At the first study visit, the subject will be randomized by the OHSU Research Pharmacy to receive either 6 weeks of 80mg atorvastatin or 6 weeks of 80mg of simvastatin. The subject will be scheduled for follow-up 6 weeks from the trial entry date and asked to bring the investigational drug vial back at the next visit. The subjects will also be given a diary to record their daily dose of medication taken. A urine pregnancy test will be done at the first and third study visit in all women who are not post-menopausal as defined as at least 6 months without menstruation over the age of 50. Women who do not meet the post-menopausal criteria, are sexually active and not on any form of birth control will be counseled to begin and remain on birth control for the duration of the trial. Inability or unwillingness to comply with chosen birth control measures will result in exclusion from the trial. Women of child bearing potential not on birth control at the time of the screening visit who are willing to begin birth control will be scheduled for their first study visit not sooner than 6 weeks after their screening visit to allow time for implementation of chosen birth control. Subjects who are on hormone replacement therapy (HRT) will be allowed to enroll provided that their regimen is stable and not expected to change during the study period. Subjects will be informed that if their regimen does change during the study, they will need to be removed from the study.